Kaneoka Ayaka, Okada Etsuko, Sugino Hitomi, Saito-Sasaki Natsuko, Omoto Daisuke, Nakamura Motonobu
Department of Dermatology, University of Occupational and Environmental Hearth, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyusyu 807-8555, Japan.
Diagnostics (Basel). 2022 Feb 13;12(2):480. doi: 10.3390/diagnostics12020480.
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab, have drastically changed treatments of advanced melanoma. However, ICI-related enterocolitis is often the most common adverse event, and represents the main reason for ICI discontinuation and mortalities. Here, we report the case of a metastatic melanoma treated with vedolizumab for ICI-induced colitis. A 67-year-old man treated with ipilimumab and nivolumab developed ICI-induced colitis and grade 3 diarrhea refractory to methylprednisolone and infliximab. After his third dose of vedolizumab, oral prednisolone ceased, and the colitis had completely resolved with no recurrence. This case report supports vedolizumab use in treating severe colitis which failed to resolve with first- and second-line immunosuppressive therapy.
免疫检查点抑制剂（ICIs），如纳武单抗和伊匹单抗，已彻底改变了晚期黑色素瘤的治疗方法。然而，ICI相关的小肠结肠炎通常是最常见的不良事件，也是ICI停药和导致死亡的主要原因。在此，我们报告一例用维多珠单抗治疗ICI诱导的结肠炎的转移性黑色素瘤病例。一名接受伊匹单抗和纳武单抗治疗的67岁男性发生了ICI诱导的结肠炎以及对甲泼尼龙和英夫利昔单抗难治的3级腹泻。在他第三次注射维多珠单抗后，口服泼尼松龙停用，结肠炎已完全缓解且未复发。本病例报告支持维多珠单抗用于治疗一线和二线免疫抑制治疗未能缓解的严重结肠炎。
